Trial · NCT06326190
177Lu-DOTATATE for Recurrent Meningioma
NCT06326190, Phase 2, Recruiting, European Organisation for Research and Treatment of Cancer - EORTC
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. 177Lu-DOTATATE for Recurrent Meningioma. Trials, record NCT06326190. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06326190
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- 177Lu-DOTATATE for Recurrent Meningioma
- NCT number
- NCT06326190
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 136 participants, estimated
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Conditions
- Recurrent Meningioma
- Interventions
- Local standard of Care, 177Lu-DOTATATE
- First posted
- 2024-03-22
- Last updated
- 2026-06-15
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | From the date of randomization till the date of disease progression or death (time till death is up to 2 years after patient enrolment in the study) | To examine whether \[177Lu\]Lu-DOTATATE demonstrates sufficient antitumor activity in patients with recurrent meningioma to justify further investigation. Progression-free survival computed based on MRI-based RANO meningioma response criteria as assessed by the local investigator. |
| Secondary | Overall Survival (OS) | From the date of randomization till the date of death (time till death is up to 2 years after patient enrolment in the study) | Overall survival (OS), OS probability at 6 (OS6) and 12 months (OS12), median OS (mOS) |
| Secondary | Radiological response rate | From the date of randomization till the date of disease progression or death (time till death is up to 2 years after patient enrolment in the study) | Best overall response (BOR, defined as CR, MR or PR during study treatment) rate. Complete response (CR) rate is computed by MRI based RANO meningioma response criteria as assessed by the local investigator. |
| Secondary | Radiological response rate | From the date of randomization till the date of disease progression or death (time till death is up to 2 years after patient enrolment in the study) | Median best overall response (BOR, defined as CR, MR or PR during study treatment) duration. Median complete response (CR) duration is computed by MRI based RANO meningioma response criteria as assessed by the local investigator. |
| Secondary | The magnitude of change in Health-related quality of life (HRQoL) | From the date of randomization regardless of progression status up to 2 years after patient enrolment in the study. | The magnitude of change in HRQoL in terms of global health status from EORTC QLQ-C30 during treatment. |
| Secondary | The magnitude of change in Health-related quality of life (HRQoL) | From the date of randomization regardless of progression status up to 2 years after patient enrolment in the study. | The magnitude of change in HRQoL in terms of physical functioning from EORTC QLQ-C30 during treatment. |
| Secondary | The magnitude of change in Health-related quality of life (HRQoL) | From the date of randomization regardless of progression status up to 2 years after patient enrolment in the study. | The magnitude of change in HRQoL in terms of motor disfunction from EORTC QLQ-BN20 during treatment. |
| Secondary | Neurological function (NANO scale) | From the date of randomization regardless of progression status up to 2 years after patient enrolment in the study. | Change of neurological function (NANO scale) from baseline during study treatment. |
| Secondary | Toxicity According to CTCAE Version 5.0 | From the date of randomization regardless of progression status up to 2 years after patient enrolment in the study. | This study will use the International Common Terminology Criteria for Adverse Events (CTCAE v5.0) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40774695 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06326190
GET https://conductscience.org/api/trials/v1/NCT06326190/registered